Investors
Welcome to the iCAD Investors page.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com.
2024 Investor Deck
Sign up to receive Investor Alerts.
Subscribe to receive investor alerts from iCAD, Inc.
Press Releases
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
NASHUA, N.H., April 11, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will showcase its ProFound Breast Health Suite of AI solutions, including the newly released ProFound Cloud, powered by Google Cloud and Google Health AI architecture, while also…
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
NASHUA, NH, and HALIFAX, NS, April 9, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to…
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
Study confirms iCAD’s Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms NASHUA, N.H. – April 8, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered…